The RAS/MAPK pathway was highly mutated with 40% of patients at MGUS/SMM, and 70% at MM, harbouring mutations in KRAS and NRAS. DIS3 was mutated in 30% of patients at the MM stage only (Fig. 1d). This evidence concerns the gene KRAS and Miyoshi myopathy.